Premium
Long‐term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis
Author(s) -
Samuel Didier,
Zignego AnnaLinda,
Reynes Michel,
Feray Cyrille,
Arulnaden Jean Louis,
David MarieFrançoise,
Gigou Michèle,
Bismuth Alain,
Mathieu Danielle,
Gentilini Paolo,
Benhamou JeanPierre,
Brechot Christian,
Bismuth Henri
Publication year - 1995
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840210211
Subject(s) - hbsag , hepatitis d virus , cirrhosis , medicine , liver transplantation , hepatitis d , transplantation , hepatitis b virus , hepatitis b , gastroenterology , virology , hepatitis , virus , immunology
Liver transplantation for liver diseases related to hepatitis B virus (HBV) and hepatitis delta virus (HDV) remains problematic because of the risk of viral recurrence. We report here the long‐term virological outcome of patients transplanted for HDV‐related liver cirrhosis (HDV cirrhosis). From December 1984 to December 1990, 76 patients with HDV cirrhosis underwent liver transplantation. Before transplantation, all the patients were HBsAg‐positive/anti‐HDV positive, and all but one were HBV DNA‐negative by dot blot hybridization. HDV RNA was detected by HDV RT‐PCR and liver HDAg by fluorescent HDV Ab. After transplantation, all the patients except four received continuous long‐term anti‐HBs passive immunoprophylaxis. The actuarial 5‐year survival was 88%. All patients who did not receive anti‐HBs immunoprophylaxis remained HBsAg‐positive and developed hepatitis. Among the 68 patients receiving anti‐HBs immunoprophylaxis with a minimum follow‐up of 2 months, HBsAg reappeared in 7 (10.3%) after a mean of 17 months. These seven patients developed hepatitis, with simultaneous HBV and HDV replication; and four cleared later HBsAg. Patients without HBV reinfection were studied for HDV reinfection: liver HD Ag or serum HDV RNA were present in 88% of the patients during the first year, without developing hepatitis; however, they were no longer detectable after 2 years in 95% of the patients. In conclusion, liver transplantation for HDV cirrhosis gives good results, with a 5‐year actuarial survival of 88%. Reappearance of HBsAg occurred in 13.2% and was associated with HBV and HDV reactivation and hepatitis. Among patients who remained HBsAg negative, HDV markers were detectable during the first year, without the development of hepatitis, but disappeared in the long term in most cases. (H EPATOLOGY 1995;21:333–339.)